title: Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era.
abstract: OBJECTIVE
  Primary cardiac sarcomas are rare tumors carrying poor prognosis. Resection remains the primary therapy. Especially in recent years, chemotherapy and radiation have been used adjunctively.
  
  
  METHODS
  All patients (n = 27) surgically treated for primary cardiac sarcoma at two tertiary referral centers from January 1990 to January 2006 were retrospectively reviewed.
  
  
  RESULTS
  There were 13 women and 14 men, with 26 resections and 1 palliative debulking performed. Cardiac explantation was necessary in 8 cases because of tumor location. Concomitant valve surgery (repair or replacement) or coronary artery bypass grafting was performed in 9 and 3 patients, respectively. Synchronous or staged resections of associated pulmonary metastases were performed in 6 and 2 patients, respectively. Operative mortality was 7.4% (2/27). Preoperative or postoperative chemotherapy was administered to 16 and 19 patients, respectively. At follow-up (median 22 months, range, 2-119 months), 12 patients were alive, with 7 tumor free. Among patients who underwent resection with curative intent and survived surgery (n = 24), median survival was 23.5 months (range 4-119 months). Patients who underwent surgical resection, radiofrequency ablation, or radiation treatment for tumor recurrence (local or metastatic, n = 7) had median survival of 47 months (range 16-119 months), whereas patients with no further intervention for recurrent disease (n = 7) had median survival of 25 months (range 8-34 months).
  
  
  CONCLUSIONS
  Multimodal therapy can achieve reasonable survival for patients with resected cardiac sarcomas. Patients with local tumor recurrence or metastatic disease may still benefit from aggressive treatment.
authors.affiliation: Department of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Tex 77030, USA. fbakaeen@bcm.edu
authors.forename: Faisal G
authors.initials: FG
authors.lastname: Bakaeen
authors.forename: Dawn E
authors.initials: DE
authors.lastname: Jaroszewski
authors.forename: David C
authors.initials: DC
authors.lastname: Rice
authors.forename: Garret L
authors.initials: GL
authors.lastname: Walsh
authors.forename: Ara A
authors.initials: AA
authors.lastname: Vaporciyan
authors.forename: Steven S
authors.initials: SS
authors.lastname: Swisher
authors.forename: Robert
authors.initials: R
authors.lastname: Benjamin
authors.forename: Shanda
authors.initials: S
authors.lastname: Blackmon
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Reardon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006348:Cardiac Surgical Procedures; D003131:Combined Modality Therapy; D005260:Female; D006338:Heart Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult